Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (190)	5/11/2000 9:51:00 PM
From: Jim Oravetz	Read Replies (1) of 370

Vion Pharmaceuticals Inc. (VION) received $750,000 in additional funding from the redemption of its Class B warrants, bringing the total proceeds to the company from the exercise of the warrants to $15.8 million. In a press release Thursday, Vion said a total of 2.62 million Class B warrants have been exercised. As a result of several recent financial transactions, the biopharmaceutical company now has cash resources of about $28.8 million. Elliott Associates, L.P. files Form 4 -Cashed in warrants, B 712 Fifth Avenue New York, New York 10019 Securities Acquired (A) or Disposed of (D) Amount: 78,132 (A) or (D): A Price: $6.23 5. Amount of Securities Beneficially Owned at End of Month 1,294,944 Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next